Elizabeth Kumm

A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma

Anas Younes, Julie M. Vose, Andrew D. Zelenetz et al. · British Journal of Cancer · 2010 · 129 citations · Full text

Medicine, Oncology, Pharmacology +15

Results of a Phase 2 Trial of HGS-ETR1 (Agonistic Human Monoclonal Antibody to TRAIL Receptor 1) in Subjects with Relapsed/Refractory Non-Hodgkin’s Lymphoma (NHL).

Anas Younes, Julie M. Vose, Andrew D. Zelenetz et al. · Blood · 2005 · 70 citations

Medicine, Oncology, Pharmacotherapy +13

Preclinical analyses and phase I evaluation of LY2603618 administered in combination with Pemetrexed and cisplatin in patients with advanced cancer

Emiliano Calvo, Victor J. Chen, Mark S. Marshall et al. · Investigational New Drugs · 2014 · 57 citations

Medicine, Oncology, Pharmacology +7

A phase 1b study to assess the safety of lexatumumab, a human monoclonal antibody that activates TRAIL-R2, in combination with gemcitabine, pemetrexed, doxorubicin or FOLFIRI.

Branimir I. Šikić, Heather A. Wakelee, Margaret von Mehren et al. · UCL Discovery (University College London) · 2007 · 36 citations

Life Sciences, Oncology, Pharmacology +15

Fludarabine and Cyclophosphamide Produces a Higher Complete Response Rate and More Durable Remissions than Fludarabine in Patients with Previously Untreated CLL: Intergroup Trial E2997.

Ian W. Flinn, Elizabeth Kumm, Michael R. Grever et al. · Blood · 2004 · 34 citations

Medicine, Pharmacology, Pharmacotherapy +6